Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

I am not a biotech expert, but I could not ignore the strength of Vertex's CF drug portfolio in 2022. The stock has almost doubled since then. While continuing to invest in innovative CF ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in younger ...

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has been granted FDA priority review for its investigational once-daily vanza triple combination treatment for cystic fibrosis, with a target action date set ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. However, the drugmaker ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...